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Background: The Scale to Assess Unawareness in Mental Disorder (SUMD) is widely used in clinical trials and
epidemiological studies but more rarely in clinical practice because of its length (74 items). In clinical practice, it is
necessary to provide shorter instruments. The aim of this study was to investigate the validity and reliability of the
abbreviated version of the SUMD.
Methods: Design: We used data from four cross-sectional studies conducted in several psychiatric hospitals in
France. Inclusion criteria: a diagnosis of schizophrenia based on DSM-IV criteria. Data collection: socio-demographic
and clinical data (including duration of illness, Positive and Negative Syndrome Scale, and the Calgary Depression
Scale); quality of life; SUMD. Statistical analysis: confirmatory factor analyses, item-dimension correlations, Cronbach’s
alpha coefficients, Rasch statistics, relationships between the SUMD and other parameters. We tested two different
scoring models and considered the response ‘not applicable’ as ‘0’ or as missing data.
Results: Five hundred and thirty-one patients participated in this study. The 3-factor structure of the SUMD
(awareness of the disease, consequences and need for treatment; awareness of positive symptoms; and awareness
of negative symptoms) was confirmed using LISREL confirmatory factor analysis for the two models. Internal item
consistency and reliability were satisfactory for all dimensions. External validity testing revealed that dimension
scores correlated significantly with all PANSS scores, especially with the G12 item (lack of judgement and
awareness). Significant associations with age, disease duration, education level, and living arrangements showed
good discriminant validity.
Conclusion: The abbreviated version of the SUMD appears to be a valid and reliable instrument for measuring
insight in patients with schizophrenia and may be used by clinicians to accurately assess insight in clinical settings.
Keywords: Schizophrenia, Psychometric properties, Validity, Reliability, Insight, Scale to Assess Unawareness in
Mental DisorderBackground
Lack of insight is a prevalent feature that affects ap-
proximately 30 to 50% of patients with schizophrenia
[1-4]. Impaired insight has been suggested as a predict-
ive value for poor treatment responses and outcomes in
patients with schizophrenia [1,5-7], especially by affect-
ing a patient’s quality of life [8], adherence to treatment
[9-11] and increasing the risk of relapse and re-* Correspondence: laurent.boyer@ap-hm.fr
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reproduction in any medium, provided the orhospitalisation [12,13]. On the other hand, several stud-
ies reported that high levels of insight can impair func-
tioning, hope and quality of life. It has been suggested
that these associations occur via self-stigma [14-16].
Because insight in schizophrenia is one important issue
of pharmacological and psychological treatments, its
assessment should be considered in the treatment and
in the follow-up visits of patients. In recent years,
researchers have reached a consensus on the definition
of insight, which is now considered a continuous and
multidimensional construct that includes the followingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.









Gender x x x x
Age x x x x
Disease duration x x x
Education level x x x x
Living arrangement x x x x
Symptomatology (PANSS) x x x x
Depression (CDSS) x x x
Quality of life (S-QoL18) x x x x
Insight (SUMD) x x x x
PANSS Positive and Negative Syndrome Scale, CDSS Calgary Depression Scale
for Schizophrenia, S-QoL 18 Schizophrenia Quality of Life, SUMD Scale to
Assess Unawareness in Mental Disorder.
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understanding of the need for treatment, (3) awareness of
the social consequences of mental disorders, (4) awareness
of symptoms, and (5) attribution of symptoms to a mental
disorder [1]. Among the various available tools, the Scale
to Assess Unawareness in Mental Disorder (SUMD) is
one of the most widely used instruments with satisfactory
psychometric properties to measure insight, while consid-
ering the continuous and multidimensional approaches
[17]. The SUMD is mainly used in clinical trials and epi-
demiological studies but more rarely in clinical practice
because of its relative length (74 items) [5]. In clinical
practice, it is necessary to provide shorter instruments, as
is already the case for other measurements such as quality
of life in schizophrenia [18]. Interestingly, an abbreviated
version of the SUMD (9 items) has been used by the same
authors in a large clinical study because of ‘interview time
constraints’ [5]. This abbreviated version (see Additional
file 1: Appendix) has not been validated using modern
psychometric methods, commonly used for item reduc-
tion, in addition to those of the classical test theory (i.e.,
traditional psychometric methods such as principal com-
ponent analysis and Cronbach’s alpha).
The purpose of this study was to investigate the valid-
ity and reliability of the abbreviated version of the
SUMD. As a result of this investigation, clinicians will




We established a database for four studies carried out by
members of the Schizophrenia Quality of Life Group, in
which the SUMD was used to assess patient insight.
The database included a total of 531 inpatients and
outpatients recruited from one psychiatric hospital in
Marseille, France. The inclusion criteria included the
following factors: a diagnosis of schizophrenia according
to the DSM-IV criteria [19], age over 18 years, informed
consent to participate, and French as their native lan-
guage. The exclusion criteria included the following fac-
tors: a diagnosis other than schizophrenia on Axis I of
the DSM-IV, a decompensated organic disease and men-
tal retardation. These studies were approved by the local
and national ethics committees (Comité de Protection
des Personnes Sud-Méditerranée I, France: trial number
CM1-0512; Commission Nationale de l’Informatique
et des Libertés: CNIL number: 00–1143) and were
conducted in accordance with the Declaration of
Helsinki and French Good Clinical Practices [20].
Data collection
The data collected in the four different studies included
socio-demographic information, clinical characteristics,and self-reported questionnaires. The data collected in
each study are presented in Table 1. More specifically,
the data collected included the following information:
1. Socio-demographic information: gender, age, living
arrangement (alone or living with a partner/parents),
and education level (primary/high school versus
university level).
2. Clinical characteristics: duration of illness, psychotic
symptoms based on the Positive and Negative
Syndrome Scale (PANSS), which comprises three
different subscales (positive, negative and general
psychopathology) [21,22]; higher scores indicate
more severe symptomatology. Another clinical
characteristic is depression based on the Calgary
Depression Scale for Schizophrenia (CDSS), which is
a nine-item scale specifically designed for patients
with schizophrenia that evaluates depression
independently of extra-pyramidal and negative
symptoms [23,24].
3. Quality of life was assessed using the S-QoL18
questionnaire [18]. The S-QoL is a specific, self-
administered and multidimensional QoL
questionnaire designed for people with
schizophrenia and comprising 18 items [18,25].
Index score range from 0, indicating the lowest QoL,
to 100, the highest QoL.
4. Insight was assessed by using the abbreviated
version of the SUMD [5], which is a standardised
expert-rating scale based on a patient interview
and comprises 9 items (current awareness of
the following states): 1. a mental disorder,
2. consequences of a mental disorder, 3. effects of
drugs, 4. hallucinatory experiences, 5. delusional
ideas, 6. disorganised thoughts, 7. blunted affect,
8. anhedonia, and 9. lack of sociability. Each item
was encoded in the same way with respect to the
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or missing data), aware (response of ‘1’), slightly
aware/unaware (response of ‘2’), and seriously
unaware (response of ‘3’).
Statistical analysis
Two scoring models
We tested two different models of scoring. As proposed
by the authors of the SUMD [5], the first model of scor-
ing (model 1) considered the response ‘not applicable’ to
be ‘0’, thereby classifying an individual as less severe
than an individual with a response of ‘1’ (aware). The
second model of scoring (model 2) considered the re-
sponse ‘not applicable’ as missing data, thereby classify-
ing an individual as unconcerned. For model 2, data
imputation was performed (due to the increased rate of
missing data, which did not permit validation of the scale)
considering data as missing not at random (MNAR) and
using a method based on the Item Response Theory (IRT)
models such as the one parameter logistic model [26].
This method determines the parameter estimate from the
observed responses (completed items in the SUMD). The
distribution of the responses for each cell in the data table
was determined to be πi,j(θv), or the estimated probability
that the subject Sv with his true degree of insight θv gives
the response j on item Ii. The values used for the imput-
ation of missing data were then drawn randomly from the
estimated distribution of each cell, with the probabilities
πi,0(θv), … , πi,c(θv), where j = 0, … , c are the c + 1 re-
sponse options. Each missing value was imputed in this
way. This procedure was then repeated five times to ob-
tain a data table combining the five imputed data tables
[27]. The item scores in these data tables were averaged.
The dimension scores were calculated using the mean
scores of all items, and an index score was obtained
using the mean values of the dimension scores. All of
the scores were linearised on a scale of 0–100, with 100
representing the highest level of unawareness and 0
representing the lowest level of unawareness.
Validation
The validation process was performed for the previously
mentioned 2 models of scoring. The validation process
included construct validity, reliability, and some aspects
of external validity. The structure of the SUMD was
explored using confirmatory factor analysis (LISREL
model), previous studies having described a 3-factor
structure of the SUMD (awareness of the disease, conse-
quences and need for treatment; awareness of positive
symptoms; and awareness of negative symptoms) [8,28].
The following indicators were required: the Root Mean
Square Error of Approximation (RMSEA) is acceptable
if <0.08 and satisfactory if <0.05, the Comparative Fit
Index (CFI) and the General Fit index (GFI) are higherthan 0.9, and the Standardised Root Mean Square Re-
sidual (SRMR) is closer to 0.
The unidimensionality of each dimension was asses-
sed using a Rasch analysis. The goodness-of-fit statistics
[inlier-sensitive fit (INFIT), ranging between 0.7 and 1.3] en-
sured that all items of the scale measured the same concept.
Internal structural validity was assessed using item-
dimension correlations. An item’s internal consistency
was assessed by correlating each item with its scale
(corrected for overlap) using Pearson’s coefficient (a cor-
relation of 0.4 was recommended for supporting item-
internal consistency [29]; an item’s discriminant validity
was assessed by determining the extent to which items
correlate more highly with the dimensions they were
supposed to represent [30]. For each dimension scale,
reliability was assessed by using Cronbach’s alpha coeffi-
cient (a coefficient of at least 0.7 was expected for each
scale [29]). Floor and ceiling effects were reported when
assessing the homogeneous repartition of the response
distribution. Proportions of missing values were pro-
vided (an acceptable rate was less than 15%). Inter-
dimensional correlations were examined using Pearson’s
and polychoric coefficients. Differential item functioning
(DIF) analyses were performed, which compared the item
differences between two groups of individuals according
to socio-demographic parameters (gender, age, education
level, disease duration, and living arrangement) to check
whether all items behave the same way [31]. The DIF
means that an item performs and measures differently for
one subgroup of a population than for the other.
The external validity was assessed by studying the rela-
tionship between dimension scores of the SUMD and
the scores of the other instruments (PANSS, CDSS, and
S-QoL18). The discriminant validity was determined by
comparing the SUMD dimension mean scores across pa-
tient groups (gender, education level, and living arrange-
ment) and by studying the correlations of the SUMD
dimension scores with age and disease duration.
Data analyses were performed using the PASW 17.0.2
computer software, Winsteps, Stata and LISREL software.
Results
Sample characteristics
Of the 531 subjects, the mean age was 38.2 years (stand-
ard deviation= 11.7), 67.8% were male, 38.8% had an
education level above the university level, 34.8% were
living alone and the average disease duration was
14.4 years (standard deviation= 9.6). These characteris-
tics are presented in Table 2.
Validity of model 1 scoring: ‘not applicable’ = ‘0’
Construct validity and reliability
A 3-factor structure was confirmed by confirmatory fac-
tor analysis. The dimensions were named according to
Table 2 Socio-demographic and clinical characteristics of the study sample (N=531)
Overall sample Study 1 (N=142) Study 2 (N=113) Study 3 (N=123) Study 4 (N=153)
n (%) or M ± SD
Gender (Male) 360 (67.8) 101 (71.1) 79 (69.9) 84 (68.3) 96 (62.7)
Age (in years) 38.2 ± 11.7 36.2 ± 12.7 38.5 ± 10.8 40.8 ± 11.5 37.6 ± 11.3
Disease duration (in years) 14.4 ± 9.6 12.3 ± 10.1 13.9 ± 8.1 17.1 ± 9.6
Education Level (University level) 206 (38.8) 67 (55.8) 51 (45.1) 27 (22.0) 61 (43.0)
Living arrangement (Alone) 185 (34.8) 44 (37.9) 46 (40.7) 50 (41.3) 45 (36.3)
PANSS Total score 69.2 ± 20.5 70.3 ± 19.9 63.9 ± 18.0 63.1 ± 21.6 77.3 ± 19.2
Positive scale score 14.9 ± 6.1 14.5 ± 5.5 14.6 ± 6.2 12.9 ± 5.9 17.1 ± 6.0
Negative scale score 17.8 ± 6.6 19.5 ± 7.3 15.8 ± 5.6 15.6 ± 6.3 19.4 ± 6.0
General psychopathology score 36.6 ± 10.9 36.3 ± 10.1 33.5 ± 9.8 34.6 ± 11.5 40.8 ± 10.6
G12 2.8 ± 1.5 3.1 ± 1.5 2.7 ± 1.4 2.4 ± 1.4 2.6 ± 1.1
CDSS Total 4.2 ± 4.1 4.0 ± 4.2 4.1 ± 4.5 4.5 ± 3.6
S-QoL18 Index 58.0 ± 18.9 57.7 ± 17.9 59.4 ± 19.4 55.0 ± 17.0 58.8 ± 20.4
M ± SD Mean ± Standard-Deviation.
PANSS Positive and Negative Syndrome Scale, CDSS Calgary Depression Scale for Schizophrenia, S-QoL 18 Schizophrenia Quality of Life.
G12 General Psychopathology Scale: Lack of judgement and awareness of the disease.
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quences and need for treatment (3 items), awareness of
positive symptoms (3 items), and awareness of negative
symptoms (3 items). This model showed a good fit, and
all the indices from the confirmatory LISREL model
were satisfactory (RMSEA=0.030, CFI=1.00, GFI=0.99,
SRMR=0.018). The model is presented in Figure 1. The
overall scalability was satisfactory; all of the items
showed a good fit for the Rasch model in each dimen-
sion, and none of the items had a statistical INFIT out-
side the range of acceptability.
Item-internal consistency was satisfactory for all di-
mensions; each item achieved the 0.40 standard for
item-internal consistency (ranging from 0.79 to 0.90).
The correlation of each item with its contributive di-
mension was higher than with the other dimensions
(item discriminant validity). Cronbach’s alpha coeffi-
cients ranged from 0.76 to 0.83, indicating satisfactory
reliability. Floor effects ranged from 4.5 to 22.3%, and
ceiling effects ranged from 11.4 to 17.1%. The percent-
age of missing data never exceeded 1%. According to the
definition of the DIF, there should be no difference on
the item behavior according to gender, age, living ar-
rangement, disease duration, and education level. Inter-
dimensional correlations were significant and ranged
from 0.39 to 0.50 (data not shown).
All the dimension characteristics of the SUMD are
provided in Table 3.
External validity
The SUMD scores showed low to medium significant
correlations with the PANSS scores (correlation coeffi-
cients ranged from 0.25 to 0.55, all p<0.01). As expected,the ‘SUMD positive symptoms’ score correlated with the
‘PANSS positive’ score (R=0.44, p<0.01), the ‘SUMD
negative symptoms’ score correlated with the ‘PANSS
negative score (R=0.44, p<0.01), and the all the SUMD
scores correlated with the specific item G12 of the
PANSS, ‘lack of judgment and conscience of the disease’
(R from 0.33 to 0.67, p<0.01). SUMD scores were either
poorly or not correlated with the depression scores and
the QoL scores. All SUMD scores were poorly correlated
with age (R from 0.13 to 0.17, p<0.01), and the two
SUMD symptom scores were poorly correlated with dis-
ease duration (R from 0.11 to 0.12, p<0.01). No signifi-
cant differences were reported regarding gender and
living arrangement, except that the ‘awareness of positive
symptoms’ score was significantly higher for the individ-
uals who reported that they lived alone. Significantly
higher levels of unawareness were found for individuals
with lower education levels, except for the awareness of
the disease, consequences and need for treatment score.
All of the details are provided in Table 4.
Validity of model 2 scoring: ‘not applicable’ = missing data
Construct validity and reliability
The 3-factor structure was retrieved. The LISREL in-
dicators were satisfactory (RMSEA=0.035, CFI=1.00,
GFI=0.99, SRMR=0.015). The LISREL model is presented
in Figure 2.
The overall scalability was satisfactory; all items showed
a good fit for the Rasch model in each dimension, and
none of the items had a statistical INFIT outside the range
of acceptability. We also noted the absence of a uniform
differential item functioning (DIF) by gender, age, living





























Figure 1 LISREL confirmatory structural model (model 1, ‘not applicable’ = ‘0’). SUMD1: Awareness of a mental disorder, SUMD2:
Awareness of the consequences of a mental disorder, SUMD3: Awareness of the effects of drugs, SUMD4: Awareness of a hallucinatory
experience, SUMD5: Awareness of delusional ideas, SUMD6: Awareness of disorganised thoughts, SUMD7: Awareness of blunted affect, SUMD8:
Awareness of anhedonia, SUMD9: Awareness of lack of sociability.
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mensions; each item achieved the 0.40 standard for
item-internal consistency, and the correlation with its
associated contributive dimension was higher than the
correlation with the other dimensions. The reliability
was satisfactory (Cronbach’s alpha coefficients > 0.70).
Floor effects ranged from 28.5% to 48.2%, and ceiling ef-
fects ranged from 11.4% to 17.1%. The missing data rate







Model 1 scoring: ‘not applicable’ = ‘0’
Awareness of disease (3) 55.3 (22.1) 0.13 0.81–0.90
Awareness of positive symptoms (3) 47.2 (27.2) 0.70 0.79–0.85
Awareness of negative symptoms (3) 47.5 (25.4) 0.53 0.81–0.87
Index (9) 50.0 (20.0) 0.45 NA***
Model 2 scoring: ‘not applicable’ = missing data
Awareness of disease (3) 56.20 (22.0) 1.6 0.82–0.93
Awareness of positive symptoms (3) 59.83 (19.6) 23.0 0.82–0.88
Awareness of negative symptoms (3) 57.45 (19.4) 15.5 0.85-0.90
Index (9) 57.83 (17.8) 13.4 NA***
*Cronbach’s Alpha, **Rasch’s statistics, ***NA Not Applicable.
M (SD) mean (standard deviation); a higher score represents a higher level of unawscores and 13.4% for the index. All of the details are pro-
vided in Table 3.
External validity
The results are similar to those found in model 1. The
SUMD scores showed low to high significant correla-
tions with the PANSS scores (correlation coefficients
ranged from 0.26 to 0.68, all p<0.01). All of the SUMD
scores were highly correlated with the specific item G12in-max)
Item discriminant
validity (min-max)
Floor % Ceiling % Alpha* INFIT**
(min-max)
0.32–0.44 4.5 17.1 0.83 0.86–1.15
0.37–0.48 22.3 15.3 0.76 0.88–1.09
0.31–0.44 16.8 11.3 0.80 0.87–1.12
NA*** NA*** NA*** 0.85 NA***
0.43–0.70 48.2 17.1 0.87 0.73–1.39
0.52–0.68 28.5 15.3 0.82 0.93–1.10
0.43–0.67 35.2 11.4 0.85 0.81–1.14
NA*** NA*** NA*** 0.85 NA***
areness.








Model 1 scoring: ‘not applicable’ = ‘0’
PANSS Total score 0.395** 0.482** 0.436** 0.550**
Positive score 0.261** 0.437** 0.251** 0.402**
Negative score 0.373** 0.348** 0.440** 0.483**
General psychopathology score 0.373** 0.454** 0.415** 0.521**
G12 0.677** 0.471** 0.333** 0.592**
CDSS total score −0,019 0.098 0.139** 0.095
S-QoL18 Index 0.009 −0.091 −0.180* −0.115*
Age 0,132** 0.149** 0.134** 0.173**
Disease duration 0,032 0.112* 0.116* 0.109
Gender Male 55.79 (22.2) 46.47 (27.7) 46.80 (25.2) 49.68 (19.9)
Female 54.13 (22.0) 48.70 (26.1) 48.86 (25.8) 50.56 (20.2)
p-value 0.419 0.377 0.382 0.634
Education level University level 53.45 (21.9) 43.07 (27.2) 42.98 (25.5) 46.50 (20.1)
High school/primary school level 55.61 (21.9) 49.89 (26.7) 50.63 (24.9) 52.04 (19.7)
p-value 0.278 0.006 0.001 0.002
Living arrangement Alone 55.62 (21.3) 50.87 (27.7) 47.33 (25.8) 51.27 (20.4)
Not alone 53.96 (22.1) 43.91 (26.7) 46.49 (25.8) 48.11 (19.7)
p-value 0.420 0.007 0.731 0.094
Model 2 scoring: ‘not applicable’ = missing data
PANSS Total score 0.389** 0.465** 0.365** 0.465**
Positive score 0.260** 0.355** 0.290** 0.344**
Negative score 0.370** 0.428** 0.382** 0.450**
General psychopathology score 0.364** 0.420** 0.296** 0.413**
G12 0.676** 0.682** 0.501** 0.697**
CDSS total score −0.007 0.045 −0.058 −0.007
S-QoL18 Index 0.001 0.001 0.010 0.005
Age 0.124** 0.112** 0.162** 0.152**
Disease duration 0.035 −0.002 0.074 0.039
Gender Male 56.87 (22.0) 60.49 (19.6) 57.42 (19.0) 58.26 (17.4)
Female 54.81 (22.1) 58.45 (19.6) 57.50 (20.5) 56.92 (18.5)
p-value 0.315 0.264 0.962 0.419
Education level University level 54.34 (22.3) 58.03 (19.8) 54.52 (18.7) 55.63 (17.8)
High/Primary school level 56.66 (21.6) 60.56 (19.4) 59.25 (19.3) 58.82 (17.6)
p-value 0.244 0.156 0.007 0.047
Living arrangement Alone 56.94 (21.1) 62.17 (19.8) 59.06 (18.8) 59.39 (17.4)
Not alone 54.73 (22.3) 57.82 (19.4) 56.52 (19.6) 56.36 (17.8)
p-value 0.283 0.018 0.164 0.069
G12 General Psychopathology Scale: Lack of judgement and awareness of the disease.
PANSS Positive and Negative Syndrome Scale, CDSS Calgary Depression Scale for Schizophrenia, S-QoL 18 Schizophrenia Quality of Life.
Bold values p<0,05, *p<0.05, **p<0.01.
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scores were not correlated with the depression and QoL
scores. All SUMD scores were correlated with age, whileno SUMD scores correlated with the disease duration.
Regarding model 1, no significant differences were





























Figure 2 LISREL confirmatory structural model (model 2, data imputation). SUMD1: Awareness of a mental disorder, SUMD2: Awareness of
the consequences of a mental disorder, SUMD3: Awareness of the effects of drugs, SUMD4: Awareness of a hallucinatory experience, SUMD5:
Awareness of delusional ideas, SUMD6: Awareness of disorganised thoughts, SUMD7: Awareness of blunted affect, SUMD8: Awareness of
anhedonia, SUMD9: Awareness of lack of sociability.
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was significantly higher for individuals who reported that
they lived alone). Significantly higher levels of unaware-
ness were found for individuals with lower education
levels for the awareness of negative symptoms index. All
of the details are provided in Table 4.
Discussion
In this study, we demonstrated the validity and reliability
of the abbreviated version of the SUMD in a series of
analyses. The internal structure, which was supported by
a high internal consistency, confirmed that patient
insight is a multidimensional concept [1]. As described
in previous studies [8,28], the 3 dimensions of the
SUMD (i.e. awareness of the disease, consequences and
need for treatment; awareness of positive symptoms; and
awareness of negative symptoms) were confirmed by
LISREL model. Moreover, the internal consistency reli-
ability of the three dimensions was proven to be high.
External validity, which was explored through the use of
socio-demographic characteristics and established psy-
chiatric and QoL measures, generally confirmed as-
sumptions made by previous researchers. As in our
findings, a lack of insight has been associated with
prolonged illness duration [32] and an increased severity
of positive and negative symptoms [5,33-36]. Olderpatients presented a lesser degree of insight regardless of
disease duration (data not shown, no interaction be-
tween age and disease duration) suggesting a specific
effect of age on insight. However, previous studies have
also reported that older individuals have better insight
[37,38]. In addition, we found a link between a lack of
insight and lower education levels, as was also found in
several previous studies [35,39-41]. This finding suggests
that more-educated patients are more likely to be better
equipped to make accurate self-assessments and to
evaluate their illness [39]. Concerning the relationship
between insight and QoL, existing studies have revealed
contradictory results. As previously determined [42-45],
we found higher QoL scores for patients who presented
higher levels of insight. Other reports, however, have
found either no relationship between QoL and insight
[46-48] or an inverted relationship between these two
factors [49-52] Finally, DIF analyses were satisfactory
and revealed a noteworthy property that has rarely been
studied in other questionnaires. We speculate that items
of the SUMD have equivalent measurement properties
according to the patients’ characteristics (i.e. the same
probability to answer a same response to an item, for a
same level of underlying insight). Therefore, the abbrevi-
ated version of the SUMD met the standards for psycho-
metric properties, suggesting that this shortened scale
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clinical practices.
The validation process of the SUMD poses serious
problems for psychometric analyses because not all
items are rated for every patient. As a consequence,
missing values (MVs) are frequent and make it difficult
to perform data analysis. Inappropriate handling of the
MVs in the analysis may bias the results and can suggest
misleading conclusions being drawn from a research
study. It may also limit one’s ability to generalise the re-
search findings [53]. We thus treated the MVs in two
different ways to guarantee the robustness of our results.
Model 1 considered the response ‘not applicable’ to be
‘0’ (less severe than an individual with a response of ‘1’ -
aware). Although replacing ‘not applicable’ with 0 was
proposed by the authors of the SUMD [5], this choice
may be criticised because 0 does not correspond to the
measure of insight but rather to the absence or presence
of symptoms. We have thus chosen to remove zero
values and replace them with MVs. MVs were particu-
larly high for awareness of positive symptoms (23%),
awareness of negative symptoms (16%), and the index
(13%), which constituted problems in terms of construct
validity and reliability testing of the scale [54]. Therefore,
we considered data imputation methods using the Item
Response Theory models to treat the present MVs before
applying the classification methods. MVs were filled in with
estimated ones based on the observed responses for the
other items of the SUMD. The validation process, including
construct validity, reliability, and some aspects of external
validity, was performed for the 2 models, and the indicators
of these two models generally matched, thereby confirmed
the robustness of our findings. These two models with 0 or
MVs appear valid and may be used alternatively by clini-
cians and researchers. A short statement about the descrip-
tion of the model should also be included in each study to
avoid confusion in the interpretation of scores.
Finally, one feature of the abbreviated version of the
SUMD, in comparison to the longer version, is its
narrower definition of insight, which does not assess the
attribution phenomenon. Indeed, the long version is of
particular interest because of its multidimensional ap-
proach to defining insight and its detailed assessment of
patients’ awareness of and attributions for a wide range
of signs and symptoms [17]. The long version of the
SUMD is one of the longest instruments (74 items)
among various insight measures, including the insight
and treatment attitude questionnaire (ITAQ, 11 items)
[2], the schedule for the assessment of insight (SAI, 3
items) [1], the positive and negative syndrome scale
(PANSS, 1 item) [21], the Soskis scale (6 items) [55], the
self-report insight scale for psychosis (ISP, 3 items) [56],
and the insight scale (IS, 32 items) [57,58]. According to
several authors, a short form of a scale is frequentlyassociated with better acceptability in clinical practices
[59]. The abbreviated version of the SUMD (9 items) may
appear to be more practical than the long version and
could lead to the inclusion of insight assessments as a part
of routine clinical practice to offer individualised care.
Strengths and limitations
There are several strengths and limitations of this study.
The large size of our sample (N = 531) may better guaran-
tee the robustness of the instrument validation results across
the large spectrum of patients with schizophrenia. Although
a large number of insight instruments have already been
validated for patients with schizophrenia, their process of
validation has often used small study samples. For example,
the validation of the long version of the SUMD was initially
conducted using 43 patients [17] and more recently using
100 patients [60]. The ITAQ was validated among 52 pa-
tients [2], the ISP among 30 patients [56], and the IS among
43 [57] and 64 patients [58]. However, even with the large
overall sample size used in this study, one may question
whether it is representative of the patient population
because participants were recruited only in France.
Several psychometric properties were not tested. In
particular, inter-judge reliability is an important property
for expert-rating scales such as the SUMD. Previous
studies have, however, shown a satisfactory inter-judge
reliability for the long version of the SUMD [17,60]. Sen-
sitivity to change is also of particular interest for patient
follow-ups in clinical practices and should thus be
explored in future studies.
Finally, an important aspect of our study was the choice
of our method to treat MVs. Indeed, a variety of mecha-
nisms and methods to handle missing data exists and could
be used. First, three data mechanisms have been proposed
[61]: missing at random (MAR), missing completely at ran-
dom (MCAR), and missing not at random (MNAR). Our
choice to consider a MNAR mechanism may be criticised
by other researchers. However, the Little’s MCAR test
obtained for our dataset indicated that the data was not
missing at random (data not shown, p < 0.001) [62]. In
addition, we felt that our choice was more appropriate
because the missing data depend on the patient’s health
status, and these data may thus be considered not random
[63]. On the other hand, several methods to impute data
are also available. The classical approach to imputing data
is imputation by mean score, which is a technique known
to be inefficient when the rate of missing data is too high,
as shown in our study [64]. We therefore chose to use a
IRT model-based multiple imputation technique, which
yielded more robust and unbiased results [63].
Conclusion
The abbreviated version of the SUMD is not intended to
replace the long version of the SUMD, which proposes a
Michel et al. BMC Psychiatry 2013, 13:229 Page 9 of 10
http://www.biomedcentral.com/1471-244X/13/229more detailed assessment of patient insight. The abbre-
viated version of the SUMD appears to be a practical,
valid and reliable instrument for measuring insight in
patients with schizophrenia and may be used by clini-
cians to accurately and consistently assess insight in a
clinical setting.
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